ModivCare, Inc.

On May 4, 2023, ModivCare released its first quarter 2023 financial results, revealing that it had experienced a reduction of cash flow from operations. On this news, ModivCare’s stock price fell $11.30, or 16.3%, to close at $58.00 per share on May 4, 2023, thereby injuring investors.

Then, on August 3, 2023, after market hours, ModivCare released its second quarter 2023 financial report, disclosing that the Company had experienced the expansion of a “large payable balance” that had impacted its cash flow from operations during the quarter. On this news, ModivCare’s stock price fell $2.86, or 7.5%, to close at $35.38 per share on August 4, 2023.

Then, on February 23, 2024, ModivCare released its fourth quarter 2023 financial results, revealing that the Company suffered negative cash flow during the quarter, and that the trend was expected to continue for the first half of fiscal year 2024. On this news, ModivCare’s stock price fell $17.25, or 39.3%, to close at $26.62 per share on February 23, 2024.

Then, on September 12, 2024, ModivCare disclosed that it would “undertak[e] actions to seek additional capital, including filing a shelf registration statement” with the SEC to improve its liquidity. On this news, ModivCare’s stock price fell $18.43, or 59.1%, to close at $12.76 per share on September 12, 2024.

Then, on September 16, 2024, ModivCare provided a financial update, revising its 2024 Adjusted EBITDA guidance range from $185–$195 million to $170–$180 million, “primarily due to NEMT segment pricing accommodations made to strategically retain and expand key customer relationships.” On this news, ModivCare’s stock price fell $1.40, or 9.9%, to close at $12.72 per share on September 16, 2024, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) certain contracts used in ModivCare’s NEMT segment caused the Company’s free cash flow to deteriorate; (2) contract renegotiations and pricing accommodations negatively impacted the Company’s adjusted EBITDA; (3) the Company had insufficient liquidity; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.